SALL4在原发性肝癌诊治中的价值

邵玥明; 张雨; 殷鑫; 温晓玉

doi:10.3969/j.issn.1001-5256.2019.10.041

SALL4在原发性肝癌诊治中的价值

DOI: 10.3969/j.issn.1001-5256.2019.10.041

吉林大学第一医院肝胆胰内科

基金项目:

吉林省科技计划项目基金(20190201065JC)；

详细信息

中图分类号: R735.7;R730.43
计量
- 文章访问数: 1246
- HTML全文浏览量: 17
- PDF下载量: 247
- 被引次数: 0
出版历程
- 收稿日期: 2019-05-20
- 出版日期: 2019-10-20

Value of Sal-like 4 in the diagnosis and treatment of primary liver cancer

Department of Hepatology,The First Hospital of Jilin University

Research funding:

摘要

摘要: SALL4是一种维持干细胞自我更新和多能性的转录因子。它在胎肝中表达但在成年人肝脏中表达沉默。目前已发现SALL4在多种实体瘤中具有诊断价值。这些特征赋予了它作为肝癌肿瘤标志物的可能。回顾了近年来SALL4在原发性肝癌发生、进展、转移等生物学过程中的作用,及其对原发性肝癌预后的预测作用。随着研究的深入,SALL4及相关microRNA可能成为诊断、治疗原发性肝癌及预测预后的新型标志物。
- 肝肿瘤 /
- SALL4 /
- 诊断 /
- 治疗学
Abstract: Sal-like 4(SALL4) is a transcription factor that helps to maintain self-renewal and pluripotency of stem cells. This gene is expressed in the human fetal liver,but is silent in the healthy adult liver. It has been reported that SALL4 has a diagnostic value in a variety of solid tumors. These characteristics make SALL4 a possible tumor biomarker for liver cancer. This article reviews the recent advances in the role of SALL4 in the development,progression,metastasis,and other biological processes of primary liver cancer,as well as its role in predicting the prognosis of primary liver cancer. We believe that with further studies,SALL4 and related microRNAs may become new markers for the diagnosis,treatment,and prognostic evaluation of primary liver cancer.
- liver neoplasms /
- SALL4 /
- diagnosis /
- therapeutics

HTML全文

参考文献(25)

[1] National Health and Family Planning Commission of the People’s Republic of China. Diagnosis,management and treatment of heptocellular carcinoma(V2017)[J]. J Clin Hepatol,2017,33(8):1419-1431.(in Chinese).中华人民共和国国家卫生和计划生育委员会.原发性肝癌诊疗规范(2017年版)[J].临床肝胆病杂志,2017,33(8):1419-1431.

[2] TATETSU H,KONG NR,CHONG G,et al. SALL4,the missing link between stem cells,development and cancer[J].Gene,2016,584(2):111-119.

[3] MA C,WANG F,HAN B,et al. SALL1 functions as a tumor suppressor in breast cancer by regulating cancer cell senescence and metastasis through the NuRD complex[J]. Mol Cancer,2018,17(1):78.

[4] TSUNEKAZU O,AKIHIDE K,SEI K,et al. Sall4 regulates cell fate decision in fetal hepatic stem/progenitor cells[J]. Gastroenterology,2009,136(3):1000-1011.

[5] MA YP,CUI W,YANG JC,et al. SALL4,a novel oncogene,is constitutively expressed in human acute myeloid leukemia(AML)and induces AML in transgenic mice[J]. Blood,2006,108(8):2726-2735.

[6] LI A,JIAO Y,YONG KJ,et al. SALL4 is a new target in endometrial cancer[J]. Oncogene,2015,34(1):63-72.

[7] YONG KJ,GAO C,LIM JSJ,et al. Oncofetal gene SALL4 in aggressive hepatocellular carcinoma[J]. N Engl J Med,2013,368(24):2266-2276.

[8] YAKABOSKI E,JARES A,MA Y. Stem cell gene SALL4 in aggressive hepatocellular carcinoma:A cancer stem cell-specific target?[J]. Hepatology,2014,60(1):419-421.

[9] MASUDA S,SUZUKI K,IZPISUA BELMONTE JC. Oncofetal gene SALL4 in aggressive hepatocellular carcinoma[J]. N Engl J Med,2013,369(12):1170-1172.

[10] OIKAWA T,KAMIYA A,ZENIYA M,et al. Sal-like protein 4(SALL4),a stem cell biomarker in liver cancers[J]. Hepatology,2013,57(4):1469-1483.

[11] HAN SX,WANG JL,GUO X,et al. Serum SALL4 is a novel prognosis biomarker with tumor recurrence and poor survival of patients in hepatocellular carcinoma[J]. J Immunol Res,2014,2014:262385.

[12] SHIBAHARA J,ANDO S,HAYASHI A,et al. Clinicopathologic characteristics of SALL4-immunopositive hepatocellular carcinoma[J]. Springerplus,2014,3:721.

[13] LIU TC,VACHHARAJANI N,CHAPMAN WC,et al. SALL4 immunoreactivity predicts prognosis in Western hepatocellular carcinoma patients but is a rare event:A study of 236 cases[J]. Am J Surg Pathol,2014,38(7):966-972.

[14] ZENG SS,YAMASHITA T,KONDO M,et al. The transcription factor SALL4 regulates stemness of EpCAM-positive hepatocellular carcinoma[J]. J Hepatol,2014,60(1):127-134.

[15] PARK H,LEE H,SEO AN,et al. SALL4 expression in hepatocellular carcinomas is associated with EpCAM-positivity and a poor prognosis[J]. J Pathol Transl Med,2015,49(5):373-381.

[16] JUNG YK,JANG K,PAIK SS,et al. Positive immunostaining of Sal-like protein 4 is associated with poor patient survival outcome in the large and undifferentiated Korean hepatocellular carcinoma[J]. Ann Surg Treat Res,2016,91(1):23-28.

[17] YIN F,HAN X,YAO SK,et al. Importance of SALL4 in the development and prognosis of hepatocellular carcinoma[J].World J Gastroenterol,2016,22(9):2837-2843.

[18] WANG H,KOHASHI K,YOSHIZUMI T,et al. Coexpression of SALL4 with HDAC1 and/or HDAC2 is associated with underexpression of PTEN and poor prognosis in patients with hepatocellular carcinoma[J]. Hum Pathol,2017,64:69-75.

[19] LIU BH,JOBICHEN C,CHIA CSB,et al. Targeting cancer addiction for SALL4 by shifting its transcriptome with a pharmacologic peptide[J]. Proc Natl Acad Sci U S A,2018,115(30):e7119-e7128.

[20] DENG G,ZHU L,HUANG F,et al. SALL4 is a novel therapeutic target in intrahepatic cholangiocarcinoma[J]. Oncotarget,2015,6(29):27416-27426.

[21] MOEINI A,SIA D,ZHANG ZY,et al. Mixed hepatocellular cholangiocarcinoma tumors:Cholangiolocellular carcinoma is a distinct molecular entity[J]. J Hepatol,2017,66(5):952-961.

[22] TANAKA Y,AISHIMA S,KOHASHI K,et al. Spalt-like transcription factor 4 immunopositivity is associated with epithelial cell adhesion molecule expression in combined hepatocellular carcinoma and cholangiocarcinoma[J]. Histopathology,2016,68(5):693-701.

[23] ZHOU WY,ZOU BK,LIU LS,et al. MicroRNA-98 acts as a tumor suppressor in hepatocellular carcinoma via targeting SALL4[J]. Oncotarget,2016,7(45):74059-74073.

[24] LI Y,LI RH,FU XY,et al. MicroRNA-33b inhibits cell proliferation in hepatocellular carcinoma via targeting SALL4[J]. J Cent South Univ(Med Sci),2016,41(9):905-910.(in Chinese)李艳,李荣华,符小玉,等. MicroRNA-33b通过靶向调控SALL4的表达抑制肝细胞癌细胞增殖[J].中南大学学报(医学版),2016,41(9):905-910.

[25] SUN C,LAN P,HAN Q,et al. Oncofetal gene SALL4 reactivation by hepatitis B virus counteracts miR-200c in PD-L1-induced T cell exhaustion[J]. Nat Commun,2018,9(1):1241.

施引文献

资源附件(0)

访问统计